Top news of the week: 29.09.2021.
Companies And Industries
ViiV Aims for Quarterly HIV Treatments with New Molecule
FDA approved ViiV Healthcare’s Cabenuva as the very first once-a-month injection for HIV patients. But the Research Triangle pharma isn’t satisfied yet.
Pharma in the Courts: Takeda, AbbVie, RedHill, Pfizer and Gilead
Aside from the fraud trial of Theranos founder Elizabeth Holmes, other court-related cases are taking place, including between Takeda and AbbVie over cancer drug, Lupron.
Rumors of Potential $11 Million Acceleron Buyout Picking Up Speed
The rumors had already been percolating as Acceleron’s stock has risen over the past 10 days from $130-a-share in mid-September to $167.65 as the market closed on Friday.
New Capricor Data Signals Hope for Difficult-to-Treat DMD Population
On Friday morning, Capricor announced positive final data from the HOPE-2 trial of its drug candidate, CAP-1002, indicating a slowing of disease progression in this population.
Clinical Catch-Up: September 20-24
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
Implications of the Elizabeth Holmes Trial on High-Risk Fundraising in Silicon Valley
Industry watchers question why Elizabeth Holmes has been singled out for failing to deliver what she promised while other tech executives are given a pass.
Chutes & Ladders—Novartis loses 2 leaders, one to MiroBio, another to a video game company
Carolin Barth, M.D., left a 17-year run at Novartis, most recently leading commercial and pipeline strategy for cell and gene therapies, to be the CEO of MiroBio. Novartis also lost Chief ...
Fierce Biotech's 2021 Fierce 15
COVID-19 was inevitably the focus of Fierce 15 last year. This year, it’s pretty much more of the same as we see how the sector has and continues to navigate the pandemic while raising ...